Vertex Pharmaceuticals Incorporated $VRTX Shares Purchased by Focus Partners Wealth

Key Points

• Focus Partners Wealth increased its stake in Vertex Pharmaceuticals by 1.8%, owning 143,205 shares worth approximately $69.43 million at the end of the most recent quarter.
• Analysts have mixed views on Vertex Pharmaceuticals with a consensus rating of "Moderate Buy", setting varying price targets ranging from $439.00 to $530.00.
• The company's stock performance shows stability with a market capitalization of $99.62 billion and recent earnings surpassing analyst expectations with a reported EPS of $4.52.

Focus Partners Wealth lifted its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 143,205 shares of the pharmaceutical company's stock after buying an additional 2,471 shares during the quarter. Focus Partners Wealth owned approximately 0.06% of Vertex Pharmaceuticals worth $69,430,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Quent Capital LLC boosted its position in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock valued at $249,000 after purchasing an additional 22 shares in the last quarter. Advisor OS LLC raised its position in Vertex Pharmaceuticals by 4.4% during the first quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company's stock valued at $263,000 after acquiring an additional 23 shares in the last quarter. Sculati Wealth Management LLC raised its position in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock valued at $1,029,000 after acquiring an additional 25 shares in the last quarter. Avidian Wealth Enterprises LLC grew its holdings in Vertex Pharmaceuticals by 2.1% in the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock valued at $594,000 after purchasing an additional 25 shares during the period. Finally, Strategic Blueprint LLC grew its holdings in Vertex Pharmaceuticals by 1.7% in the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock valued at $726,000 after purchasing an additional 25 shares during the period. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Scotiabank reduced their price objective on Vertex Pharmaceuticals from $442.00 to $438.00 and set a "sector perform" rating on the stock in a research report on Tuesday, August 5th. UBS Group set a $553.00 price objective on Vertex Pharmaceuticals and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Guggenheim decreased their target price on Vertex Pharmaceuticals from $558.00 to $546.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. Wall Street Zen cut Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday, August 22nd. Finally, JPMorgan Chase & Co. increased their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $496.05.

Vertex Pharmaceuticals Stock Down 0.7%

NASDAQ VRTX traded down $2.84 during mid-day trading on Friday, hitting $394.53. The stock had a trading volume of 978,279 shares, compared to its average volume of 1,386,885. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The company has a market cap of $101.15 billion, a price-to-earnings ratio of 28.20 and a beta of 0.44. The company has a 50 day simple moving average of $422.66 and a 200 day simple moving average of $453.56.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals's revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the business posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs acquired 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 0.20% of the stock is currently owned by corporate insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.